CR20240375A - Conjugados anticuerpo-fármaco y sus usos - Google Patents
Conjugados anticuerpo-fármaco y sus usosInfo
- Publication number
- CR20240375A CR20240375A CR20240375A CR20240375A CR20240375A CR 20240375 A CR20240375 A CR 20240375A CR 20240375 A CR20240375 A CR 20240375A CR 20240375 A CR20240375 A CR 20240375A CR 20240375 A CR20240375 A CR 20240375A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibody
- drug conjugates
- drug
- conjugates
- ovarian
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305279 | 2022-03-11 | ||
| PCT/EP2023/056097 WO2023170247A1 (en) | 2022-03-11 | 2023-03-10 | Antibody-drug conjugates and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20240375A true CR20240375A (es) | 2025-01-06 |
Family
ID=80979142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20240375A CR20240375A (es) | 2022-03-11 | 2023-03-10 | Conjugados anticuerpo-fármaco y sus usos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250302978A1 (https=) |
| EP (1) | EP4489788A1 (https=) |
| JP (2) | JP7706668B2 (https=) |
| KR (1) | KR20240168351A (https=) |
| CN (1) | CN119173279A (https=) |
| AU (1) | AU2023231442A1 (https=) |
| CA (1) | CA3245732A1 (https=) |
| CL (1) | CL2024002655A1 (https=) |
| CO (1) | CO2024012022A2 (https=) |
| CR (1) | CR20240375A (https=) |
| DO (1) | DOP2024000178A (https=) |
| IL (1) | IL314828A (https=) |
| JO (1) | JOP20240199A1 (https=) |
| MX (1) | MX2024011013A (https=) |
| PE (1) | PE20251386A1 (https=) |
| WO (1) | WO2023170247A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240091372A1 (en) * | 2022-07-19 | 2024-03-21 | Seoul National University R&Db Foundation | Anti-doppel antibody drug conjugates |
| AU2024263367A1 (en) | 2023-04-27 | 2025-11-13 | CSPC Megalith Biopharmaceutical Co., Ltd. | Antibody-drug conjugate |
| EP4534102A1 (en) * | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| EP4534101A1 (en) * | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| FR3164899A1 (fr) * | 2024-07-24 | 2026-01-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
| CN120737008B (zh) * | 2025-09-04 | 2025-11-11 | 韶远科技（上海)有限公司 | 一种(S)-4-[2-(Boc-氨基)-1-羟基乙基]-2-硝基苯酚及其制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5658920A (en) | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| EP3423105B1 (en) * | 2016-03-02 | 2021-05-05 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
| BR112020003466B1 (pt) | 2017-08-31 | 2023-12-12 | Daiichi Sankyo Company, Limited | Métodos de produção de composto, e, composto |
| JP7423513B2 (ja) * | 2017-09-18 | 2024-01-29 | ストロ バイオファーマ インコーポレーテッド | 抗葉酸受容体α抗体コンジュゲート及びその使用 |
| JP7381478B2 (ja) | 2017-10-23 | 2023-11-15 | マブリンク ビオシオンス | 単一分子量ポリサルコシンを含むリガンド－薬物－複合体 |
| CN112125915A (zh) | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
| US20240216525A1 (en) * | 2021-03-30 | 2024-07-04 | Mablink Bioscience | Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological properties |
-
2023
- 2023-03-10 CR CR20240375A patent/CR20240375A/es unknown
- 2023-03-10 PE PE2024001907A patent/PE20251386A1/es unknown
- 2023-03-10 JP JP2024551627A patent/JP7706668B2/ja active Active
- 2023-03-10 IL IL314828A patent/IL314828A/en unknown
- 2023-03-10 AU AU2023231442A patent/AU2023231442A1/en active Pending
- 2023-03-10 CA CA3245732A patent/CA3245732A1/en active Pending
- 2023-03-10 MX MX2024011013A patent/MX2024011013A/es unknown
- 2023-03-10 CN CN202380039749.4A patent/CN119173279A/zh active Pending
- 2023-03-10 US US18/844,818 patent/US20250302978A1/en active Pending
- 2023-03-10 WO PCT/EP2023/056097 patent/WO2023170247A1/en not_active Ceased
- 2023-03-10 EP EP23710874.1A patent/EP4489788A1/en active Pending
- 2023-03-10 KR KR1020247033958A patent/KR20240168351A/ko active Pending
-
2024
- 2024-09-03 CO CONC2024/0012022A patent/CO2024012022A2/es unknown
- 2024-09-04 CL CL2024002655A patent/CL2024002655A1/es unknown
- 2024-09-11 JO JOJO/P/2024/0199A patent/JOP20240199A1/ar unknown
- 2024-09-11 DO DO2024000178A patent/DOP2024000178A/es unknown
-
2025
- 2025-07-01 JP JP2025111263A patent/JP2025148380A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240168351A (ko) | 2024-11-29 |
| PE20251386A1 (es) | 2025-05-22 |
| JP2025148380A (ja) | 2025-10-07 |
| CO2024012022A2 (es) | 2024-09-19 |
| CL2024002655A1 (es) | 2025-05-23 |
| IL314828A (en) | 2024-10-01 |
| DOP2024000178A (es) | 2024-11-29 |
| JP2025509142A (ja) | 2025-04-11 |
| AU2023231442A1 (en) | 2024-09-26 |
| US20250302978A1 (en) | 2025-10-02 |
| WO2023170247A1 (en) | 2023-09-14 |
| JP7706668B2 (ja) | 2025-07-11 |
| MX2024011013A (es) | 2024-09-17 |
| CA3245732A1 (en) | 2023-09-14 |
| EP4489788A1 (en) | 2025-01-15 |
| JOP20240199A1 (ar) | 2024-09-11 |
| CN119173279A (zh) | 2024-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024002655A1 (es) | Conjugados anticuerpo-fármaco y sus usos | |
| MX2020010408A (es) | Conjugados de anticuerpo-farmaco y sus usos para el tratamiento del cancer. | |
| JOP20210074A1 (ar) | مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها | |
| MX2023005645A (es) | Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer. | |
| CY1119324T1 (el) | Αντισωματα εναντιον csf-1r | |
| EA200701250A1 (ru) | Иммуноконъюгаты против интегрина, способы и варианты применения | |
| PE20170517A1 (es) | Conjugados de anticuerpo-farmaco-anti-ptk7 | |
| MX2023008327A (es) | Anticuerpos inmunomoduladores de anticuerpo-farmaco. | |
| CL2022000038A1 (es) | Conjugados peptídicos de citotoxinas como terapéuticos. | |
| MX2020011487A (es) | Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos. | |
| JOP20240261A1 (ar) | مترافقات جسم مضاد عقار لمركبات مضادة للورم وطرق استخدامها | |
| CO2022001315A2 (es) | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos | |
| CO2025004991A2 (es) | Anticuerpo anti-gucy2c y usos del mismo | |
| CO2025008047A2 (es) | Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos | |
| BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário | |
| MX2009007617A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
| MX2009007618A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
| MX2024012413A (es) | Conjugados de anticuerpo-farmaco basados en eribulina y metodos de uso | |
| MX2023008426A (es) | Polipeptidos variantes de actinohivina y metodos relacionados. | |
| MX2025005210A (es) | Anticuerpos anti-avb6 y conjugados anticuerpo-fármaco y su uso en el tratamiento del cáncer | |
| AR132465A1 (es) | Anticuerpos lilrb1 y lilrb2 y métodos de uso de estos | |
| MX2009009919A (es) | Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma. | |
| PE20252676A1 (es) | Conjugado anticuerpo-farmaco que se une a her3 | |
| AR071847A1 (es) | Anticuerpos monoclonales modificadores de enfermedades cancerosas | |
| AR070280A1 (es) | Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab) |